BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 22454318)

  • 1. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations.
    Thol F; Kölking B; Damm F; Reinhardt K; Klusmann JH; Reinhardt D; von Neuhoff N; Brugman MH; Schlegelberger B; Suerbaum S; Krauter J; Ganser A; Heuser M
    Genes Chromosomes Cancer; 2012 Jul; 51(7):689-95. PubMed ID: 22454318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.
    Abdelhamid E; Preudhomme C; Helevaut N; Nibourel O; Gardin C; Rousselot P; Castaigne S; Gruson B; Berthon C; Soua Z; Renneville A
    Leuk Res; 2012 Mar; 36(3):316-23. PubMed ID: 22129478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data.
    Spencer DH; Abel HJ; Lockwood CM; Payton JE; Szankasi P; Kelley TW; Kulkarni S; Pfeifer JD; Duncavage EJ
    J Mol Diagn; 2013 Jan; 15(1):81-93. PubMed ID: 23159595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia.
    Schiller J; Praulich I; Krings Rocha C; Kreuzer KA
    Eur J Haematol; 2012 Jul; 89(1):53-62. PubMed ID: 22458420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
    Schneider F; Hoster E; Schneider S; Dufour A; Benthaus T; Kakadia PM; Bohlander SK; Braess J; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Feuring-Buske M; Buske C; Creutzig U; Thiede C; Zwaan MC; van den Heuvel-Eibrink MM; Reinhardt D; Hiddemann W; Spiekermann K
    Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FMS-like tyrosine kinase 3 internal tandem duplication and the patterns of its gene sequence in 207 Chinese patients with de novo acute myeloid leukemia.
    Zhong L; Jia YQ; Meng WT; Ni X
    Arch Pathol Lab Med; 2012 Jan; 136(1):84-9. PubMed ID: 22208491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia.
    Bibault JE; Figeac M; Hélevaut N; Rodriguez C; Quief S; Sebda S; Renneville A; Nibourel O; Rousselot P; Gruson B; Dombret H; Castaigne S; Preudhomme C
    Oncotarget; 2015 Sep; 6(26):22812-21. PubMed ID: 26078355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlation of FLT3 gene expression level and internal tandem duplication mutation in acute myeloid leukemia and its clinical significance].
    Wang YG; Liu XH; Liang Y; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):741-5. PubMed ID: 19176010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of
    Grob T; Sanders MA; Vonk CM; Kavelaars FG; Rijken M; Hanekamp DW; Gradowska PL; Cloos J; Fløisand Y; van Marwijk Kooy M; Manz MG; Ossenkoppele GJ; Tick LW; Havelange V; Löwenberg B; Jongen-Lavrencic M; Valk PJM
    J Clin Oncol; 2023 Feb; 41(4):756-765. PubMed ID: 36315929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients.
    Zuffa E; Franchini E; Papayannidis C; Baldazzi C; Simonetti G; Testoni N; Abbenante MC; Paolini S; Sartor C; Parisi S; Marconi G; Cattina F; Bochicchio MT; Venturi C; Ottaviani E; Cavo M; Martinelli G
    Oncotarget; 2015 Oct; 6(31):31284-94. PubMed ID: 26384303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Establishment of a rapid and easy method for simultaneous detection of FLT3-ITD and NPM1 gene mutations in acute myeloid leukemia].
    Lu Y; Wang Q; Mu QT; Yu MX; Huang Q; Jin J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Apr; 29(2):163-6. PubMed ID: 22487825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia.
    Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Chang WH
    Cancer; 2002 Jun; 94(12):3292-8. PubMed ID: 12115363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, correlation with cytogenetics and characterization of internal tandem duplication from Indian population.
    Ahmad F; Mandava S; Das BR
    Cancer Invest; 2010 Jan; 28(1):63-73. PubMed ID: 19995225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.
    Del Poeta G; Ammatuna E; Lavorgna S; Capelli G; Zaza S; Luciano F; Ottone T; Del Principe MI; Buccisano F; Maurillo L; Panetta P; de Fabritiis P; Stasi R; Venditti A; Amadori S; Lo Coco F
    Br J Haematol; 2010 May; 149(3):383-7. PubMed ID: 20148885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia.
    Scholl S; Loncarevic IF; Krause C; Kunert C; Clement JH; Höffken K
    Leuk Res; 2005 Jul; 29(7):849-53. PubMed ID: 15921740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics.
    Huang Q; Chen W; Gaal KK; Slovak ML; Stein A; Weiss LM
    Br J Haematol; 2008 Jul; 142(3):489-92. PubMed ID: 18477048
    [No Abstract]   [Full Text] [Related]  

  • 20. Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype.
    Haferlach T; Bacher U; Alpermann T; Haferlach C; Kern W; Schnittger S
    Leuk Res; 2012 Jan; 36(1):51-8. PubMed ID: 21621842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.